Overview
Brivudine is a synthetic nucleoside analogue developed as an antiviral agent, specifically active against varicella-zoster virus (VZV) which causes shingles. It was first synthesized in the 1970s and has been used clinically in several European countries. The compound works by being phosphorylated by viral thymidine kinase, then inhibiting viral DNA polymerase more effectively than human DNA polymerase. As a thymidine analogue, brivudine incorporates into viral DNA during replication, causing chain termination. Its selectivity for viral over human enzymes gives it a favorable therapeutic index. While primarily used against VZV, it has shown some activity against other herpesviruses in laboratory studies.
Physical and Chemical Properties
Brivudine appears as a white to off-white crystalline powder with moderate stability under recommended storage conditions. The molecular structure contains a bromovinyl group at the 5-position of the uracil ring, which is critical for its antiviral activity. The compound shows characteristic UV absorption at 278 nm. Its solubility profile makes it suitable for pharmaceutical formulation, being slightly soluble in water (approximately 2 mg/mL at 25°C) but more soluble in organic solvents like DMSO. The melting point with decomposition around 230°C indicates reasonable thermal stability for normal handling conditions. The logP value (approximately 0.5) suggests moderate lipophilicity.
Main Applications
The primary medical use of brivudine is for the treatment of acute herpes zoster (shingles) in immunocompetent adults. Clinical studies have demonstrated its efficacy in reducing viral shedding and accelerating lesion healing. It is typically administered orally in tablet form (125 mg once daily for 7 days). In research contexts, brivudine serves as a tool compound for studying herpesvirus replication mechanisms. Its unique mechanism of action makes it valuable for investigating viral thymidine kinase and DNA polymerase functions. Some studies have explored its potential against Epstein-Barr virus and other herpesviruses, though these remain investigational applications.
Safety and Storage
Brivudine requires careful handling due to its pharmacological activity. Personal protective equipment including gloves and safety glasses should be worn when handling the powder form. The compound should be stored in a cool (2-8°C), dry environment in airtight containers protected from light to prevent degradation. A critical safety consideration is the absolute contraindication with 5-fluorouracil (5-FU) or related compounds, as brivudine strongly inhibits dihydropyrimidine dehydrogenase (DPD), leading to potentially fatal 5-FU toxicity. Other adverse effects may include gastrointestinal disturbances and mild liver enzyme elevations. Proper disposal should follow pharmaceutical waste regulations.
B2B Procurement Guide
When procuring brivudine for pharmaceutical use, buyers must verify GMP certification and proper documentation including certificates of analysis (CoA) and stability data. The API should meet pharmacopeial standards (EP/USP) with specified purity (typically ≥98%). For research applications, analytical grade material (≥95% purity) may be acceptable from reputable chemical suppliers. Bulk quantities (100g+) often require special ordering. Lead times can vary from 2-8 weeks depending on supplier inventory. Import/export may require special permits due to its pharmaceutical classification. Pricing is typically quoted per gram with volume discounts available for larger orders.